BEAM Alliance, Biotechs of Europe innovating in Anti-Microbial Resistance

Are Clinical Endpoints Truly Fit-for-Purpose? In the fast-evolving world of drug development, are we using the right clinical endpoints to evaluate new treatment options? This question is particularly pressing in the case of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)—an indication where small differences in various parameters could have significant impact for different stakeholders. Join us at AMR Conference for the session "Clinical Endpoints: Fit-for-Purpose?", where top experts will challenge the status quo and explore whether current endpoints are truly fit for purpose - or if we need to rethink them. 🔍 Rienk Pypstra tranScrip will moderate a session where: 💡 Clare Nasmyth-Miller Roche will share real-world insights, questioning if current endpoints effectively capture all important benefits. 📊 Dr. Radu Botgros European Medicines Agency will represent the regulatory perspective and examine why existing endpoints are supported, opening the debate: What should stay? What’s missing? 🔬 Marc Bonten will introduce Ecraid, showcasing how it can play a role in selecting and validating improved endpoints. If you’re in drug development, infectious diseases, or regulatory affairs, this is a session you won’t want to miss. Let’s rethink clinical endpoints together! 📅 Join the conversation and register today! https://lnkd.in/de_vAkF   #ClinicalTrials #DrugDevelopment #RegulatoryAffairs #HAP #VAP #Endpoints

🎯 The Future of Dose Finding in Drug Development: A Must-Attend Session for Innovators In the rapidly evolving world of drug development, traditional phase II dose-finding studies are no longer the gold standard. Today, translational models are leading the charge - leveraging in vitro data, killing kinetics, animal models, and human pharmacokinetics to design smarter, more effective treatment regimens. For combination therapies, this innovative approach means maximized efficacy, fewer side effects, and significant cost savings—a game-changer, especially in the fight against antimicrobial resistance (AMR), where every penny matters. 👩🔬 Join us at this dynamic session, ✅ Alasdair MacGowan (North Bristol NHS Trust): Translational PK/PD and finding the right dose regimen. ✅ Anouk Muller (Haaglanden Medisch Centrum (HMC) Medical Centre): Selecting the optimal regimen for fixed-dose combinations. In the follow-up podium discussion Markus Zeitlinger (Medical University of Vienna) will lead the discussion on critical aspects to take into account when interacting with regulatory agencies on the topic. 💡 Why attend? 🔹Discover cutting-edge approaches to dose optimization. 🔹Learn how to save resources while improving patient outcomes. 🔹Engage with leading experts shaping the future of drug development. 👉 Don’t leave your next regimen to chance - secure your spot now and be part of the discussion driving innovation in AMR and beyond! Register here: https://lnkd.in/de_vAkF #DrugDevelopment #AMR #antimicrobialresistance

🔬 Can a multi-country PULL mechanism work in the EU? 💊 The fight against antimicrobial resistance (AMR) needs bold incentives. Revenue guarantees are PULL mechanisms that are gaining traction globally, with the UK pioneering an enhanced model and several pilots being tested worldwide. But what about the EU? A pilot project was planned but ran into hurdles. Can we still make it happen at the EU level? If so, how? Join us for the session "Towards an EU multi-country PULL mechanism", moderated by Grace Hampson Office of Health Economics, where leading experts will share insights: 📌 Pol Vandenbroucke – Lessons learned by Shionogi Europe from different pilots and what’s attractive, what’s not 📌 Jasper Claessen Dutch Ministry of Health, Welfare and Sport – Member State’s perspective on the available options from a policy and political viewpoint 📌 Wolfgang Philipp European Commission – What happened with the pilot setup by DG HERA, and why was it halted? 📌 Najy Alsayed MD, M.Sc. Alsayed – MENARINI Group’s experience of the pilot and comparison with the newly announced Italian scheme Finding a viable EU-wide model is crucial for reviving innovation in AMR. Let's explore the road ahead together. Don't miss this pivotal discussion! https://lnkd.in/de_vAkF #AMR #Innovation #PullIncentives #HealthPolicy #EU #AntibioticResistance

🔬 Clinical Trials: Combining Drugs, Not Problems 💊 Conducting clinical trials with multiple drug candidates presents several challenges. Drug interactions, dose optimization, and regulatory hurdles can make combination trials complex to design and execute. Stricter inclusion criteria can slow down recruitment, impacting statistical power. So, how do we navigate these obstacles? How do we ensure that combination trials lead to breakthroughs, not roadblocks? Join us for an insightful session where top experts will share lessons learned from real-world combination trials: 🎤Florence Sejourne AUROBAC THERAPEUTICS will guide the discussion on best practices and strategies 📌 Andreas Diacon TASK – Lessons from TB drug combination trials 📌 Glenn E Dale BioVersys AG – Designing combination trials for Gram-negative pathogens, with BV100 as a case study 📌 nicolas veziris Sorbonne Université – Key takeaways from non-tuberculosis mycobacteria research Don’t miss this chance to gain expert insights and refine your approach to combination therapies! Will you be there? https://lnkd.in/de_vAkF #ClinicalTrials #DrugDevelopment #Innovation #CombinationTherapy #Biopharma

🌍💊 Tackling Climate Change and Antimicrobial Resistance: A One Health Imperative Antimicrobial resistance (#AMR) and climate change are two of the most pressing global health challenges of our time. Did you know they are deeply interconnected? 🌡️ Climate change accelerates the spread of infectious diseases, disrupts ecosystems, and strains healthcare systems—all of which can amplify the development and spread of AMR. This is why a One Health approach, recognizing the ties between human, animal, and environmental health, is essential. At our upcoming AMR Conference, we’ll host an in-depth session exploring the synergies between combating AMR and addressing climate change. Here’s what’s on the agenda: ✅ Climate-resilient policies and their role in AMR mitigation ✅ Cross-sector collaboration for sustainable global health solutions ✅ Cutting-edge research at the AMR-environment nexus ✅ Case study on the impacts of climate change on health systems & AMR ✨ Expert Panelists: 👉 Yewande Alimi, Africa CDC 👉 Aula Abbara, Imperial College London 👉 Sarah Tschudin Sutter, University Hospital Basel 👉 Tine Rikke Jorgensen University of Copenhagen (Københavns Universitet) Moderated by Caline Mattar, with support from Global AMR R&D Hub, this discussion will inspire action to safeguard global health resilience. Join us to be part of this vital conversation and help shape innovative strategies to tackle AMR in the era of climate change. 📅 Don’t miss this opportunity to connect, learn, and lead. Will we see you there? Register here: https://lnkd.in/de_vAkF #OneHealth #antimicrobial resistance #ClimateChange #GlobalHealth #Sustainability

🌍 Accelerating the Fight Against AMR: A Spotlight on Diagnostic Innovation 🌟 Join us at the AMR Conference to discover cutting-edge diagnostic technologies reshaping the battle against antimicrobial resistance (AMR). This session brings together top innovators tackling the urgent need for rapid, cost-effective, and scalable diagnostics. 💡 What you can look forward to in this session moderated by Jens Hellwage InfectoGnostics Research Campus Jena: 👉Stephane Gavoille Molsid will unveil the potential of fluorescence-based AST technology, a game-changing solution combining unprecedented speed and affordability. With its ability to scale into low- and middle-income countries (LMICs), this technology could democratize access to rapid diagnostics. 👉 Marianne Ismail will showcase how Microbira Limited’s bacteria and yeasts microorganism identification software help Combat AMR with rapid and reagent-free fluconazole resistance detection using MAAP-IR. 👉 Richard Grohs Leibniz Institute of Photonic Technology will explore on-chip Raman spectroscopy, a cutting-edge tool for fast antimicrobial susceptibility testing. By detecting resistance patterns through spectral signatures, this innovation promises to transform how we identify AMR. 👉 Neciah Dorh FluoretiQ Limited will describe how to unlock real time pathogen identification and antibiotic sensitivity by looking beyond growth-based phenotypic testing. 🌟 Why attend this session? Get inspired by breakthrough technologies poised to make diagnostics faster, more accurate, and more accessible—key factors in addressing the global AMR challenge. 📅 Don’t miss out on this dynamic discussion. Secure your spot now to connect, learn, and lead the fight against AMR! Register today! https://lnkd.in/de_vAkF   #AMR #Diagnostics #Innovation #Conference #Healthcare

🌍 Shaping a Sustainable Investment Ecosystem in Europe for AMR 🌱 Are you looking to understand the future of antimicrobial R&D investment in Europe? Don't miss this crucial session at the AMR Conference 🦠💡 Antimicrobial resistance (AMR) poses a growing threat, yet investment in AMR R&D has been in decline due to the financial hurdles of a low-volume market. European biotech companies are increasingly seeking capital outside the EU, raising concerns about the region's competitiveness in fostering antimicrobial innovation. With the EU’s renewed focus on strengthening innovation and enhancing its competitive position, this session brings together leading voices from biotech, venture capital, and public financing to explore: ✅ The challenges and opportunities of investing in AMR innovation. ✅ Strategies for building a robust and sustainable investment ecosystem in Europe. ✅ How EU initiatives like HERA Invest can help catalyze financing and innovation.   👥 Featured Panelists: Moderator: Martin Heidecker AMR Action Fund 👉 Mark E. Jones PhD PMP Basilea Pharmaceutica: Sharing insights on their dual strategy of product development and external portfolio integration.   👉 Sebastian Kreuz Boehringer Ingelheim Venture Fund & Zina Affas Besse AXA Investment Managers: Venture capital leaders offering their vision of the AMR investment landscape. 👉 Aleksandar Dajkovic: Highlighting the European Investment Bank (EIB)'s involvement through HERA Invest and other financial tools. 👉 Lloyd Payne: Exploring company creation in the antibiotic space: creating value in an underventured field. This session isn’t just a discussion—it’s a roadmap for shaping Europe’s future in AMR innovation. Be part of the conversation and contribute to solutions that matter.   🔗 Ready to learn, engage, and innovate? Register now to secure your spot: https://lnkd.in/de_vAkF   #AMR #Innovation #Investment #Sustainability #Biotech #AntimicrobialResistance #EUInnovation #VentureCapital

🚀 Past Failures, Future Successes: Lessons from AMR product development Innovation is not just about breakthroughs—it’s also about navigating failures and turning them into stepping stones. At AMR Conference, our session "Past Failures, Future Successes" will uncover real-world case studies of antimicrobial product development that didn’t go as planned—but led to invaluable lessons. 🔬 What went wrong? 🛠 How did we fix it? 🔄 If we could start over, what would we do differently? Join Erin Duffy CARB-X and an expert panel as they dissect past challenges, unexpected roadblocks, and the creative solutions that paved the way forward: ✨ Adam Johnson Centauri Therapeutics Limited will explore alternative models to determine mechanism of action and PK/PD, ensuring reproducible and justifiable exposure-response relationships—particularly crucial for non-traditional drug developments. 🦠 Saskia Janssen TASK will share the lessons learnt from the development of bedaquiline, pointing out shortcomings in its development pathway that favoured drug resistance, and why we now need to think beyond traditional antibiotics, including phage therapy. 🔍 Chandrasekhar Nair Molbio Diagnostics will share how they dealt with scaling AMR Testing, providing insights from Truenat on Regulation, Manufacturing, and Access. 💡 If you work in #AMR R&D, you need to be part of this conversation. Learn from the past to build a better future. 📅 Don’t miss out! Will we see you there? Register here: https://lnkd.in/de_vAkF #Innovation #DrugDevelopment #Antimicrobials #LessonsLearned #Conference

🌍 Innovation for Access to Effective Antibiotics: A Must-Attend Session at AMR Conference! 🧪💡 A useful innovation is one that is available to those who need it. Let’s join a dynamic session designed to equip #AMR drug developers with the insights they need to navigate country systems for successful global launches. 🌐 💬 What’s on the agenda? Our expert panel, moderated by Toby Leslie from the Fleming Fund Mott MacDonald, will explore key topics: 🔹 Stewardship, diagnostics, and implementation learnings with Kristina Osbjer The International Centre for Antimicrobial Resistance Solutions (ICARS) 🔹 Operational guidance and forecasting with Alexandra Cameron World Health Organization 🔹 Strategies and insights on inter-agency collaboration with Megan Neary Wellcome Trust 🔹 Field experience and lessons learned shared by Victoria Rutter Commonwealth Pharmacists Association 📍 Why should you attend? You’ll gain actionable insights on readiness, policy frameworks, financing strategies, and regulatory pathways—critical elements for ensuring your innovations reach those who need them most. Don’t miss this opportunity to connect with thought leaders and discover how to turn your AMR innovation into a global success story. 🌟 💡 Let’s tackle AMR together—one innovation at a time! Register today! https://lnkd.in/de_vAkF #Innovation #AMR #Antibiotics #GlobalHealth

Join the Conversation: Communication on AMR – A Simple Matter of Wording? One of the greatest challenges in tackling Antimicrobial Resistance (AMR) is not just science or policy—it's communication. How do we make this invisible threat feel real, urgent, and actionable? How can we bridge the gap between complex terms and human understanding? 📣 At AMR Conference, join the interactive discussion "Communication on AMR: A Simple Matter of Wording?" where leading voices will explore how to tell the AMR story effectively to educate, engage, and inspire action. Here’s a preview of the session: 🎤 Francesca Chiara The AMR Narrative will share strategies for empowering patient advocates to deliver impactful and relatable testimonies. 🎤 Kate Grailey from the Fleming Initiative will highlight the use of co-design methodology to best engage the public with AMR, and how we can apply this to education. 🎤 Becky McCall UCL will dive into the art of storytelling to make the AMR message resonate with all audiences. 🎤 Diane Shader Smith from the Global AMR Diary will discuss how diverse voices and experiences can unite to build a compelling, action-driving narrative. By communicating better, we can do more than inform—we can motivate stakeholders at every level to join the fight against AMR. 💡 Don’t miss this opportunity to learn, engage, and be inspired to change the way we talk about AMR! Register today! https://lnkd.in/de_vAkF #AMR #AntimicrobialResistance #Storytelling #Communication #HealthcareInnovation #PublicHealth